Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
- J. Rinehart, A. Adjei, +12 authors Mark B Meyer
- Medicine
- Journal of clinical oncology : official journal…
- 15 November 2004
PURPOSE
This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral mitogen-activated extracellular signal regulated kinase kinase (MEK)… Expand
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
- P. LoRusso, A. Adjei, +12 authors Mark B Meyer
- Medicine
- Journal of clinical oncology : official journal…
- 10 August 2005
PURPOSE
This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD), and clinical activity of CI-1040, a small-molecule inhibitor of the… Expand
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses
- N. Roberts, Linping Zhang, +35 authors S. Zhou
- Biology, Medicine
- Science Translational Medicine
- 13 August 2014
Clostridium novyi-NT targets aberrant tumor physiology and can produce a precise, robust, and reproducible antitumor response. Fighting Cancer with Clostridium Tumors are composed of necrotic,… Expand
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
- R. Sullivan, J. Infante, +24 authors B. Li
- Medicine
- Cancer discovery
- 15 December 2017
Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in BRAF- and RAS-mutant cell lines. In this multicenter phase I trial (NCT01781429), 135 patients were enrolled to… Expand
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
- E. R. Gaynor, J. Unger, +7 authors R. Fisher
- Medicine
- Journal of clinical oncology : official journal…
- 1 February 2001
PURPOSE
Two phase II studies were conducted to evaluate infusional cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy, termed the CVAD regimen, alone (Southwest Oncology Group… Expand
A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer
- P. LoRusso, S. Krishnamurthi, +7 authors M. Meyer
- Medicine
- 1 June 2005
3011 Background: Oral PD 0325901 is a potent inhibitor of the dual-specificity kinases, MEK1/2 (MAPK/ERK/Kinase), thereby preventing phosphorylation and subsequent activation of mitogen-activated p...
Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
- R. Mohammad, K. Katato, +6 authors A. Al-Katib
- Medicine
- Clinical cancer research : an official journal of…
- 1 February 1998
We have previously reported that bryostation 1 (Bryo 1) induces differentiation of chronic lymphocytic leukemia (CLL) in vitro to a hairy cell (HC) stage. This study tests the hypothesis that Bryo… Expand
Waldenström's macroglobulinemia in young African‐American adults
- S. Ahmed, M. Shurafa, C. Bishop, M. Varterasian
- Medicine
- American journal of hematology
- 1 March 1999
We have identified five African‐American patients with Waldenström's macroglobulinemia (WM) diagnosed at a young age (ages 35, 38, 38, 40, 51; 4 males, 1 female). All had a history of intravenous… Expand
Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma.
- A. Aref, S. Narayan, +5 authors A. Al-katib
- Medicine
- Radiation oncology investigations
- 1999
The purpose of this study was to evaluate the probability and extent of response to radiation therapy in patients with chemotherapy-resistant intermediate grade non-Hodgkin's lymphoma. Thirty-five… Expand
Baseline heart rate-corrected QT and eligibility for clinical trials in oncology.
- M. Varterasian, M. Meyer, +4 authors D. Healey
- Medicine
- Journal of clinical oncology : official journal…
- 1 September 2003